Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial

Published 2012 View Full Article

Authors

Keywords

Journal

LANCET

Volume 379, Issue 9835, Pages 2429-2438

Publisher

Elsevier BV

Online

2012-06-29

DOI

10.1016/s0140-6736(12)60918-0

Ask authors/readers for more resources

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

LANCET

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Become a Peeref-certified reviewer

Ask a Question. Answer a Question.